Immunotherapy has been an emerging treatment for metastatic melanoma and several other malignancies since 2015. Hematological immune-mediated adverse effects from immunotherapy are rarely reported but they can cause serious harm to patients. Antibodies such as ipilimumab, nivolumab and pembrolizumab target different immune checkpoints to promote T cell anti-tumour response. In particular, pembrolizumab is an antibody that inhibits programmed cell death receptor 1 (PD-1) to upregulate tumour suppression. In this report, we present a case of pembrolizumab-induced autoimmune hemolytic anemia and pancytopenia in a patient who was receiving pembrolizumab treatment for metastatic melanoma. This patient has a history of chronic lymphocytic leukemia and was diagnosed with metastatic melanoma in 2017. He developed symptomatic AIHA and pancytopenia after receiving 8 cycles of pembrolizumab in 2018. Pembrolizumab treatment was discontinued and he was treated with blood transfusion and prednisone. After 5 months of tapering prednisone treatment, his Case Rep Oncol 2019;12:456-465 
Introduction
Immunotherapy has emerged as one of the hot topics of cancer treatment since the approval of ipilimumab in 2011, and subsequently PD-a inhibitors. There are several categories of immunotherapy: monoclonal antibodies, non-specific immunotherapies, oncolytic virus therapy, T-cell therapy, and cancer vaccines, some of which are still in the clinical trial phase [1] [2] [3] [4] . Monoclonal antibodies play a large role in the treatment of metastatic melanoma by serving as checkpoint inhibitors to promote T cell activation and upregulate T cell antitumor responses to suppress tumours. Since 2015, the US Food and Drug Administration (FDA) has approved three checkpoint inhibitor drugs for the treatment of metastatic melanoma, each inhibitor targeting different "brakes" of the T-cell activation pathway. Ipilimumab targets the cytotoxic T-lymphocyte antigen 4 (CTLA-4), while pembrolizumab and nivolumab target the programmed cell death receptor 1 (PD-1). Somatic mutations in melanoma are associated with presentation of cancer-specific antigens, and these antigens appeared to be the target for checkpoint inhibitor-reactivated immune cells [5] . Immunotherapy for metastatic cancer is not without its downfalls; the activated immune cells may also produce autoimmune reaction against healthy cells in different organs. Immune mediated adverse events have been reported and each immunotherapeutic drug seem to have distinctly different adverse effects, for example, gastrointestinal adverse effects are commonly reported in ipilimumab but not in pembrolizumab or nivolumab [6] . As immunotherapy can affect a whole range of systems in the body, it is necessary for physicians to document and report adverse events. In this case, we present one of the first reported case of pembrolizumab-induced pancytopenia and autoimmune hemolytic anemia (AIHA).
Case Report
A 67-year-old male with a past medical history of chronic lymphocytic leukemia (CLL) , and diagnosed BRAF negative metastatic melanoma in 2017 on pembrolizumab as first line treatment was presenting with shortness of breath. He presented to his medical oncology follow-up on his 8th cycle of the pembrolizumab with 1 week history of worsening fatigue and shortness of breath initially on exertion and then at rest. Routine laboratory investigations showed a hemoglobin of 66 g/L that morning at the end of June, which was quite a decrease from his baseline hemoglobin of 154 g/L as well as normal LDH (Fig. 1 ). The patient was sent to the emergency department to be assessed by hematology. He received a 1g dose of methylprednisone IV and red cell transfusion. Supportive management was done. Investi-gations showed that his absolute reticulocyte count was 12.8 × 10 -9 /L (N = 20-90) ( Fig. 2) . Peripheral blood film reflected normocytic anemia and no spherocytic hemolysis were seen on smear. Bone marrow biopsy found bone marrow involvement by the low-grade B-cell lymphoma and reduced and left shifted erythropoiesis, and the biopsy did not reflect red cell aplasia at the time.
Two weeks later, His hemoglobin was 83 g/L , white cell count 4.2 x10 -9 /L (N = 4.5-11), platelets 45 × 10 -9 L (N = 150-450), ANC 1.5 × 10 -9 L (1.5-8 L) ( Fig. 1 ). Due to the continued anemia, neutropenia and thrombocytopenia, the medical team decided to start him on prednisone at a dose of 1 mg/kg/day.
The hematologist suspected two components to his symptoms: PD-1 inhibitor use in the background of CLL. As a result he developed an evolving to aplastic anemia, with a component of autoimmune hemolytic anemia.
Two months after the emergency visit, he was followed up by the hematologist that noted bone marrow suppression -which was slowing recovering given the rising reticulocyte count and hemolytic anemia; likely autoimmune given positive direct antiglobulin test (DAT) and response to prednisone.
Two weeks into his prednisone taper, there was a rise in his LDH and haptoglobin so the team extended the prednisone duration. When his prednisone taper was finished in October, his WBC was 13.3 × 10 -9 /L, hemoglobin 112 g/L, platelet 220 × 10 -9 /L, and lymphocyte 8.8 × 10 -9 /L ( Fig. 1 ). He was found to have an enlarging pulmonary nodule and a referral was in put for stereotactic radiation. He continued to have weekly CBCs to monitor for anemia. He restarted on prednisone twice for a decrease in his hemoglobin as soon as tapering is attempted.
Discussion
In our case report, we have a 67-year-old male with pre-existing CLL who was found to have anemia, thrombocytopenia and neutropenia after 8 cycles of pembrolizumab, an anti-PD-1 immunotherapy, for his metastatic melanoma. He was diagnosed with autoimmune hemolytic anemia (AIHA) based on positive DAT result and positive response to prednisone. Pancytopenia due to aplastic anemia was also diagnosed based on hypocellular finding on bone biopsy. After discontinuation of pembrolizumab and treatment with blood transfusion and ongoing steroids, he is responded appropriately with rising RBC and reticulocyte count.
The cause of AIHA is idiopathic for a majority of patients. Other causes include drugs, malignancy, autoimmune disorders, and infections [19] . The diagnostic criteria include a positive DAT, laboratory finding supporting hemolysis such as increase in serum lactate dehydrogenase (LDH), and reticulocytosis and spherocytosis on peripheral blood smears [20] .
Acquired pancytopenia can be caused by decreased production of cells, or by pooling and destruction of cells. Production of cells can be decreased by leukemia, aplastic anemia, nutritional deficiency, bone metastasis, fulminant sepsis, and myelodysplastic syndrome. Pooling/destruction of cells can be caused by splenomegaly, paroxysmal nocturnal hemoglobinuria, or acquired hemophagocytic lymphohistiocytosis [21] .
There have been several reported cases of drug induced AIHA or pancytopenia due to pembrolizumab since anti-CTLA-4 and anti-PD-1 immunotherapies were approved by the FDA in 2011.
To this date, pembrolizumab has three reported cases of hematologic adverse effect from the treatment of different cancers. In 2016, Nair et al. reported AIHA with pure red cell aplasia after 3 cycles of pembrolizumab for malignant melanoma; In 2017, Atwal et al. reported pancytopenia after 18 cycles of pembrolizumab. In 2018, Ogawa et al. reported exacerbation of AIHA after 1 cycle of pembrolizumab treatment for lung adenocarcinoma. In these cases, recovery from anemia was achieved with the use of a combination of steroids, IVIG, RBC transfusion, and platelet transfusion [7] [8] [9] . A summary of adverse effects of PD-1 inhibitors used in patients with melanoma can be found in Table 1 .
Nivolumab, the other anti-PD-1 antibody therapy, has similar reports of adverse hematologic reaction. There is a total of eleven cases to date detailing either AIHA or pancytopenia as the adverse reaction. Only 5/11 of the patients resolved their anemia or pancytopenia with steroid and transfusion, and the remaining six patients either expired from their pre-existing illness before anemia improved, or still have persistent pancytopenia with bone marrow failure. In 2017, Michot et al. described three patients who had unresolved anemia, one of which died from febrile neutropenia from abdominal sepsis [15] . In 2016, Palla et al. described a patient who was refractory to steroid therapy and died due to her cancer before the AIHA can be corrected [14] . In 2018, Tokumo et al. also described a patient who died from progression of lung cancer after onset of pancytopenia before he could resolve his pancytopenia [18] . A summary of adverse effects of PD-1 inhibitors used in patients with other malignancies can be seen in Table 2 .
Pembrolizumab and nivolumab are antibodies that binds to PD-1 receptors to block the PD-1 receptor pathway, a pathway that leads to the downregulation of immune reactions to tumours. As a result, anti-PD-1 antibodies will reverse T-cell suppression and induce anti-tumour responses.
It is suggested that the blockade of PD-1 will enhance the T-effector cells in tissues and tumour microenvironments [22] . Studies have also shown an association between the inhibition of PD-1 pathway and increase in B cell activity and cytokine level [23, 24] . Hemolysis in our case can be explained by activation of pre-existing RBC specific T-effector cells or B cells by the anti-PD-1 antibodies. In addition to peripheral origins for cytopenia (AIHA and autoimmune thrombocytopenia), Michot et al. in 2017 found bone marrow failure in 3 cases of nivolumab therapy for melanoma, suggesting a central origin for immune-related cytopenia in bone marrow suppression as well [15] .
Our case is one of the first ever reported case of drug induced AIHA and pancytopenia due to pembrolizumab. In our patient, hemolytic anemia and aplastic anemia due to bone marrow suppression were both present, suggesting PD-1 antibodies can affect RBC counts both peripherally and centrally.
Our patient does have chronic lymphocytic leukemia, and it is possible that the cytopenia is attributed to a masked progression to CLL. However, the CLL was stable and the patient did not have signs of CLL progression prior to the initiation of pembrolizumab treatment. Lymphocytosis was present in the lab work taken at baseline and after his symptoms emerged.
Although adverse effects were noted, re-challenging with the same PD-1 inhibitor can yield different results. Khan et al. re-challenged a patient with ipilimab and nivolumab, and patient redeveloped AIHA [16] . Conversely, Tardy et al. re-challenged a patient with nivolumab without recurrence of AIHA [17] . The mechanism by which autoimmune hemolysis is activated needs further studies.
Reported hematologic toxicities are rare but they can be fatal for pembrolizumab. These reports demonstrate the potential hematologic toxicity of immunotherapy, and they call for increased monitoring for the safety of patients, and familiarity with the rescue treatment for pancytopenia and AIHA caused by PD-1 inhibitors.
Conclusion
Cancer patients face greater risk of immunosuppression with standard chemotherapy treatment compared to the general population. With the advance of immunotherapy for metastatic melanoma and other malignancies, a number of immuned-related AIHA and pancytopenia have been reported with PD-1 inhibitors. Physicians should be aware of the risk of hematologic toxicity and immunosupression when they prescribe immunotherapy, and execise appropriate monitoring to optimize patient safety.
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